A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2

Journal of Virology

Volumn 88, Issue 1, 2014, Pages 325-338

  Hervé, Pierre Louis ^a   Raliou, Mariam ^a   Bourdieu, Christiane ^a   Dubuquoy, Catherine ^a   Petit Camurdan, Agnès ^a   Bertho, Nicolas ^a   Eléouët, Jean François ^a   Chevalier, Christophe ^a   Riffault, Sabine ^a  

^a INRA Institut National de la Recherche Agronomique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; MATRIX PROTEIN 2; NANOPARTICLE; SUBNUCLEOCAPSID NANORING; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DOSE COMPARISON; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS LOAD; VIRUS NUCLEOCAPSID; VIRUS STRAIN; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MUCOUS MEMBRANE; NANOSTRUCTURES; NUCLEOCAPSID; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84890881156     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01141-13     Document Type: Article

References (50)

1. Belyakov IM, Ahlers JD. 2009. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183:6883-6892. http://dx.doi.org/10.4049/jimmunol.0901466.
2. Lycke N. 2012. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12:592-605. http://dx.doi.org/10 .1038/nri3251.
3. Schneider-Ohrum K, Ross TM. 2012. Virus-like particles for antigen delivery at mucosal surfaces. Curr. Top. Microbiol. Immunol. 354:53-73. http://dx.doi.org/10.1007/82_2011_135.
4. Scheerlinck J-PY, Greenwood DLV. 2008. Virus-sized vaccine delivery systems. Drug Discov. Today 13:882-887. http://dx.doi.org/10.1016/j .drudis.2008.06.016.
5. Bachmann MF, Jennings GT. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10:787-796. http://dx.doi.org/10.1038/nri2868.
6. Vanlandschoot P, Cao T, Leroux-Roels G. 2003. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral Res. 60: 67-74. http://dx.doi.org/10.1016/j.antiviral.2003.08.011.
7. Tran T-L, Castagné N, Bhella D, Varela PF, Bernard J, Chilmonczyk S, Berkenkamp S, Benhamo V, Grznarova K, Grosclaude J, Nespoulos C, Rey FA, Eléouët J-F. 2007. The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J. Gen. Virol. 88:196-206. http://dx.doi .org/10.1099/vir.0.82282-0.
8. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagné N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eléouët J-F, Rey FA. 2009. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326:1279-1283. http: //dx.doi.org/10.1126/science.1177634.
9. Roux X, Dubuquoy C, Durand G, Tran-Tolla T-L, Castagné N, Bernard J, Petit-Camurdan A, Eléouët J-F, Riffault S. 2008. Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One 3:e1766. http://dx.doi.org/10.1371/journal.pone.0001766.
10. Riffault S, Meyer G, Deplanche M, Dubuquoy C, Durand G, Soulestin M, Castagné N, Bernard J, Bernardet P, Dubosclard V, Bernex F, Petit-Camurdan A, Deville S, Schwartz-Cornil I, Eléouët J-F. 2010. A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 28:3722-3734. http://dx.doi.org/10.1016/j.vaccine .2010.03.008.
11. Elderfield R, Barclay W. 2011. Influenza pandemics. Adv. Exp. Med. Biol. 719:81-103. http://dx.doi.org/10.1007/978-1-4614-0204-6_8.
12. Boni M. 2008. Vaccination and antigenic drift in influenza. Vaccine 26: C8-C14. http://dx.doi.org/10.1016/j.vaccine.2008.04.011.
13. Staneková Z, Varečková E. 2010. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 7:351. http://dx.doi.org/10.1186/1743-422X-7-351.
14. Lamb RA, Lai C-J. 1980. Sequence of interrupted and uninterrupted mRNAs and cloned DNA coding for the two overlapping nonstructural proteins of influenza virus. Cell 21:475-485. http://dx.doi.org/10.1016 /0092-8674(80)90484-5.
15. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. 2004. A "universal" human influenza A vaccine. Virus Res. 103:173-176. http://dx .doi.org/10.1016/j.virusres.2004.02.030.
16. Neirynck S, Deroo T, Saelens X. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163. http://dx.doi.org/10.1038/13484.
17. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W. 2006. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 3:102. http://dx.doi.org/10.1186/1743-422X-3-102.
18. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172:5598-5605.
19. Kang SM, Song JM, Compans RW. 2011. Novel vaccines against influenza viruses. Virus Res. 162:31-38. http://dx.doi.org/10.1016/j.virusres .2011.09.037.
20. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186: 1022-1031. http://dx.doi.org/10.4049/jimmunol.0902147.
21. Castagne N, Barbier A, Bernard J, Rezaei H, Huet J, Henry C, Da Costa B, Eléouët J. 2004. Biochemical characterization of the respiratory syncytial virus P-P and P-N protein complexes and localization of the P protein oligomerization domain. J. Gen. Virol. 85:1643-1653. http://dx.doi.org /10.1099/vir.0.79830-0.
22. Matrosovich M, Matrosovich T, Garten W, Klenk H-D. 2006. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3:63. http: //dx.doi.org/10.1186/1743-422X-3-63.
23. Remot A, Roux X, Dubuquoy C, Fix J, Bouet S, Moudjou M, Eléouët J-F, Riffault S, Petit-Camurdan A. 2012. Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine. PLoS One 7:e37722. http://dx.doi.org/10 .1371/journal.pone.0037722.
24. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W. 2005. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337:149-161. http://dx.doi.org/10.1016/j .virol.2005.04.004.
25. Parker R, Deville S, Dupuis L, Bertrand F, Aucouturier J. 2009. Adjuvant formulation for veterinary vaccines: MontanideTM Gel safety profile. Procedia Vaccinol. 1:140-147. http://dx.doi.org/10.1016/j.provac.2009 .07.026.
26. Shim B-S, Choi YK, Yun C-H, Lee E-G, Jeon YS, Park S-M, Cheon IS, Joo D-H, Cho CH, Song M-S, Seo S-U, Byun Y-H, Park H-J, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong K-J, Czerkinsky C, Song MK. 2011. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 6:e27953. http://dx.doi.org/10.1371/journal.pone.0027953.
27. Wolf AI, Mozdzanowska K, Williams KL, Singer D, Richter M, Hoffmann R, Caton AJ, Otvos L, Erikson J. 2011. Vaccination with M2ebased multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One 6:e28445. http://dx.doi.org/10.1371/journal.pone.0028445.
28. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Gerhard W. 2003. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21:2616-2626. http: //dx.doi.org/10.1016/S0264-410X(03)00040-9.
29. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W. 2007. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenzaAvirus vaccine in the mouse. Virol. J. 4:118. http://dx.doi.org/10.1186/1743 -422X-4-118.
30. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. 2009. M2e-based universal influenza A vaccine. Vaccine 27:6280-6283. http://dx.doi.org/10.1016/j.vaccine.2009.07.007.
31. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T. 2012. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS One 7:e45765. http://dx.doi.org/10.1371/journal.pone.0045765.
32. Andersson A-MC, Håkansson KO, Jensen BAH, Christensen D, Andersen P, Thomsen AR, Christensen JP. 2012. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One 7:e46395. http://dx.doi.org/10.1371/journal.pone.0046395.
33. Song J-M, Wang B-Z, Park K-M, Van Rooijen N, Quan F-S, Kim M-C, Jin H-T, Pekosz A, Compans RW, Kang S-M. 2011. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6:e14538. http://dx.doi.org/10.1371/journal.pone.0014538.
34. Jazi MHZ, Dabaghian M, Tebianian M, Gharagozlou MJ, Ebrahimi SM. 2012. In vivo electroporation enhances immunogenicity and protection against influenzaAvirus challenge of an M2e-HSP70cDNAvaccine. Virus Res. 167:219-225. http://dx.doi.org/10.1016/j.virusres.2012.05.002.
35. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin M-E, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D. 2008. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26:3395-3403. http://dx.doi.org/10.1016/j.vaccine.2008.04.052.
36. Johansson BE, Moran TM, Kilbourne ED. 1987. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenzaAvirus surface glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 84:6869-6873. http://dx.doi.org/10.1073/pnas.84.19.6869.
37. Gabbard J, Velappan N, Di Niro R, Schmidt J, Jones CA, Tompkins SM, Bradbury AR. 2009. A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng. Des. Sel. 22:189-198. http://dx.doi .org/10.1093/protein/gzn070.
38. Muto NA, Yoshida R, Suzuki T, Kobayashi S, Ozaki H, Fujikura D, Manzoor R, Muramatsu M, Takada A, Kimura T, Sawa H. 2012. Inhibitory effects of an M2-specific monoclonal antibody on different strains of influenza A virus. Jpn. J. Vet. Res. 60:71-83. http://hdl.handle .net/2115/50096.
39. De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X. 2008. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26:6503-6507. http://dx.doi.org/10.1016/j .vaccine.2008.09.038.
40. Simoes EA. 1999. Respiratory syncytial virus infection. Lancet 354:847-852. http://dx.doi.org/10.1016/S0140-6736(99)80040-3.
41. Gimenez HB, Keir HM, Cash P. 1987. Immunoblot analysis of the human antibody response to respiratory syncytial virus infection. J. Gen. Virol. 68(Part 5):1267-1275.
42. Levine S, Dajani A, Klaiber-Franco R. 1988. The response of infants with bronchiolitis to the proteins of respiratory syncytial virus. J. Gen. Virol. 69(Part 6):1229-1239.
43. Manca F, Fenoglio D, Li Pira G, Kunkl A, Celada F. 1991. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med. 173:37-48. http://dx.doi.org/10.1084/jem.173.1.37.
44. Ekiert DC, Bhabha G, Elsliger M, Friesen RHE, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251. http://dx.doi.org /10.1126/science.1171491.
45. Prabhu N, Prabakaran M, Ho H-T, Velumani S, Qiang J, Goutama M, Kwang J. 2009. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83:2553-2562. http://dx.doi.org/10.1128/JVI.02165-08.
46. Zhou D, Wu T-L, Lasaro MO, Latimer BP, Parzych EM, Bian A, Li Y, Li H, Erikson J, Xiang Z, Ertl HCJ. 2010. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol. Ther. 18:2182-2189. http://dx .doi.org/10.1038/mt.2010.202.
47. Kim M-C, Song J-M, O E, Kwon Y-M, Lee Y-J, Compans RW, Kang S-M. 2013. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 21:485-492. http://dx.doi.org/10.1038/mt.2012 .246.
48. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S-I, Kurata T, Sata T. 2004. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J. Med. Virol. 74:328-335. http://dx.doi.org/10.1002/jmv.20173.
49. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, Iwakura Y, Suzuki Y, Aizawa C, Sata T, Kurata T, Tamura S. 2002. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol. 168:2930-2938.
50. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. 2009. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83:5726-5734. http://dx.doi.org/10.1128/JVI .00207-09.